ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Beyond Basic Beta Channel
  2. Biotech Bounce-Back Might Be Durable
Beyond Basic Beta Channel
Share

Biotech Bounce-Back Might Be Durable

Tom LydonAug 17, 2022
2022-08-17

Following a lengthy wait that included plenty of downside and frustration, biotechnology stocks and exchange traded funds are finding a groove.

For example, the VanEck Vectors Biotech ETF (BBH B-) is higher by 14.23% since the start of the third quarter. There’s still work to be done as BBH is down 13.64% year-to-date, but recent price action in the biotech equity arena is undoubtedly encouraging.

Interestingly, the recent biotech rally isn’t rooted in fundamentals, which are solid in the group, as much as it is rooted in sentiment. That is to say, more positive headlines are emerging, supporting the upside for BBH and its 25 holdings.

“In a note out Friday, Jefferies analyst Michael Yee drove home the point: Of 16 biotech-sector “events” he tracked in the third quarter, 69% were good news and 31% were bad news. Compare those numbers with second-quarter ones: 38% of 56 events were good news and 62% were bad. The breakdown was even worse in the first quarter, when 26% of 46 events were good, compared with 74% that were bad,” reported Josh Nathan-Kazis for Barron’s.

Delivering punches – good news – is usually positive for companies and investors alike. However, how a company absorbs a punch – bad news – is important, too. To that, BBH and other biotech assets are showing summer temerity this summer.

The much ballyhooed Inflation Reduction Act contains a provision that will allow Medicare to negotiate with biopharma companies on prices for a slew of popular prescription drugs. In theory, that’s not positive for some BBH components, but the fund is standing firm in the wake of that news.

“And potential bad news hasn’t seemed to quash the good summertime vibes. This week, for example, President Joe Biden is planning to sign a significant piece of legislation that includes drug-pricing provisions opposed by the pharmaceutical industry,” according to Barron’s.

In order for BBH’s 25 member firms and the ETF itself to continue rallying into the fourth quarter and year-end, news flow needs to remain positive. Whether it be encouraging Food & Drug Administration (FDA) trial data or approval headlines, elevated shareholder rewards or boosted earnings and sales guidance, headlines that make investors feel good could keep the biotech fire burning over the near-term.

For more news, information, and strategy, visit the Beyond Basic Beta Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X